Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Paricalcitol in Patients With Myelodysplastic Syndromes

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	25 to 100	Other	CSMC-IRB-4107-01 NCT00064376

Trial Description

Purpose:

Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells.

Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.

Eligibility:

• 25-100 years old
• More than 5 weeks since chemotherapy, radiation therapy, and high-dose vitamins
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive paricalcitol by mouth once a day for up to 4 months. Patients will be evaluated at 1 month.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

H. Phillip Koeffler, MD, Protocol chair		Ph: 310-423-4609 Email: koeffler@cshs.org

Registry Information
Official Title		A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes
Trial Start Date		2003-05-31
Registered in ClinicalTrials.gov		NCT00064376
Date Submitted to PDQ		2003-06-05
Information Last Verified		2004-09-08

Back to Top